NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.

Miyake, Takahito M; Pradeep, Sunila; Bayraktar, Emine; Stur, Elaine; Handley, Katelyn F; Wu, Sherry Y; Rodriguez-Aguayo, Cristian; Lee, Ju-Seog; Lopez-Berestein, Gabriel; Coleman, Robert L; Sood, Anil K

Miyake, Takahito M; Pradeep, Sunila; Bayraktar, Emine; Stur, Elaine; Handley, Katelyn F; Wu, Sherry Y; Rodriguez-Aguayo, Cristian; Lee, Ju-Seog; Lopez-Berestein, Gabriel; Coleman, Robert L; Sood, Anil K.

Afiliação

Miyake TM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pradeep S; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Bayraktar E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Stur E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Handley KF; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wu SY; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rodriguez-Aguayo C; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lee JS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lopez-Berestein G; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Coleman RL; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sood AK; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Mol Cancer Ther ; 19(8): 1727-1735, 2020 08.

Article em En | MEDLINE | ID: mdl-32499298

Assuntos

Resistencia a Medicamentos Antineoplásicos; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Hidrazinas/farmacologia; Carioferinas/antagonistas & inibidores; Neuregulina-1/metabolismo; Neoplasias Ovarianas/tratamento farmacológico; Receptor ErbB-3/metabolismo; Receptores Citoplasmáticos e Nucleares/antagonistas & inibidores; Triazóis/farmacologia; Animais; Apoptose; Biomarcadores Tumorais/genética; Biomarcadores Tumorais/metabolismo; Proliferação de Células; Feminino; Perfilação da Expressão Gênica; Humanos; Camundongos; Camundongos Nus; Neuregulina-1/genética; Neoplasias Ovarianas/metabolismo; Neoplasias Ovarianas/patologia; Receptor ErbB-3/genética; Transcriptoma/efeitos dos fármacos; Células Tumorais Cultivadas; Ensaios Antitumorais Modelo de Xenoenxerto; Proteína Exportina 1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Triazóis / Regulação Neoplásica da Expressão Gênica / Receptores Citoplasmáticos e Nucleares / Resistencia a Medicamentos Antineoplásicos / Receptor ErbB-3 / Neuregulina-1 / Carioferinas / Hidrazinas Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google